Artwork

Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Colorectal Cancer | Cases from the Community: Investigators Discuss Emerging Research and Actual Patients with Colorectal Cancer

59:31
 
Share
 

Manage episode 289491445 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring perspectives from Dr Kristen K Ciombor and Prof Eric Van Cutsem, including the following topics:

  • Introduction (0:00)
  • Case: A woman in her mid-60s with microsatellite stable (MSS) right-sided metastatic colorectal cancer (mCRC) with a KRAS G13B mutation and a tumor mutation burden (TMB) of 11 mut/Mb — Warren S Brenner, MD (3:00)
  • Case: A woman in her early 60s with microsatellite instability (MSI)-high, TMB-high mCRC who achieves a response to pembrolizumab but experiences pneumonitis — Gigi Chen, MD (10:00)
  • Updated results from the Phase III KEYNOTE-177 trial of pembrolizumab and the Phase II CheckMate 142 trial of nivolumab/ipilimumab as first-line therapy for MSI-high/mismatch repair-deficient advanced CRC (16:42)
  • Case: A woman in her mid-50s with previously treated mCRC harboring KRAS and BRAF mutations who receives TAS-102/bevacizumab — Justin Peter Favaro, MD, PhD (19:39)
  • Case: A woman in her early 70s with MSI-high, PD-L1-positive mCRC harboring BRAF V600E and somatic BRCA1 mutations — Dr Brenner (27:54)
  • Efficacy and safety of TAS-102 in combination with bevacizumab as first-line therapy in the Phase II TASCO1 trial for patients with mCRC; utility of ctDNA in mCRC with a BRAF V600E mutation (36:40)
  • Case: A man in his mid-60s with asymptomatic, relapsed mCRC and a rising carcinoembryonic antigen level off treatment — Margaret Deutsch, MD (46:35)
  • Case: A woman in her early 30s with extensively treated MSS mCRC with no targetable mutations — Mamta Choksi, MD (49:15)
  • Emerging clinical trial results and future directions in the management of mCRC (53:27)

CME information and select publications

  continue reading

1440 episodes

Artwork
iconShare
 
Manage episode 289491445 series 1464173
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Featuring perspectives from Dr Kristen K Ciombor and Prof Eric Van Cutsem, including the following topics:

  • Introduction (0:00)
  • Case: A woman in her mid-60s with microsatellite stable (MSS) right-sided metastatic colorectal cancer (mCRC) with a KRAS G13B mutation and a tumor mutation burden (TMB) of 11 mut/Mb — Warren S Brenner, MD (3:00)
  • Case: A woman in her early 60s with microsatellite instability (MSI)-high, TMB-high mCRC who achieves a response to pembrolizumab but experiences pneumonitis — Gigi Chen, MD (10:00)
  • Updated results from the Phase III KEYNOTE-177 trial of pembrolizumab and the Phase II CheckMate 142 trial of nivolumab/ipilimumab as first-line therapy for MSI-high/mismatch repair-deficient advanced CRC (16:42)
  • Case: A woman in her mid-50s with previously treated mCRC harboring KRAS and BRAF mutations who receives TAS-102/bevacizumab — Justin Peter Favaro, MD, PhD (19:39)
  • Case: A woman in her early 70s with MSI-high, PD-L1-positive mCRC harboring BRAF V600E and somatic BRCA1 mutations — Dr Brenner (27:54)
  • Efficacy and safety of TAS-102 in combination with bevacizumab as first-line therapy in the Phase II TASCO1 trial for patients with mCRC; utility of ctDNA in mCRC with a BRAF V600E mutation (36:40)
  • Case: A man in his mid-60s with asymptomatic, relapsed mCRC and a rising carcinoembryonic antigen level off treatment — Margaret Deutsch, MD (46:35)
  • Case: A woman in her early 30s with extensively treated MSS mCRC with no targetable mutations — Mamta Choksi, MD (49:15)
  • Emerging clinical trial results and future directions in the management of mCRC (53:27)

CME information and select publications

  continue reading

1440 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide